In The News
At Visible Genomics, we love working with journalists to build awareness around AMD and DNA testing for macular degeneration. If you’re a member of the media and would like to talk, get in touch!
Visible Genomics Launches DNA Testing for AMD Risk - Market Scope
Written by Jenni Crabbe
“Visible Genomics, a Chicago-area genetics testing company, announced Sept. 14 that it had launched a non-invasive genetic eye test that determines a patient’s likelihood of contracting age-related macular degeneration (AMD).”
New Genetic Test For AMD - Review of Optometry
“Optometrists who want to include genetic testing in their AMD work-ups have a new option to consider. Start-up company Visible Genomics has launched a test that helps clarify a patient’s likelihood of developing AMD, according to a press release.”
Visible Genomics Launches DNA Age-Related Macular Degeneration Testing - The Optical Journal
“Visible Genomics, a Chicago-area genetics testing company has announced the launch of a new non-invasive genetic eye test that determines a patient’s likelihood of contracting Age-Related Macular Degeneration (AMD), a disease that causes blindness. AMD affects the macular, the central part of the retina, and is one of the leading causes of irreversible vision loss in the United States, affecting over 11 million Americans.”
A Way to Stop Macular Degeneration? - Innovation Toronto
“In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight. The finding may allow doctors to halt the inflammation early on, potentially saving patients from blindness”
Visible Genomics Launches DNA Age-Related Macular Degeneration Testing - Eyewire News
“Visible Genomics, a Chicago-area genetics testing company, has announced the launch of a new noninvasive genetic eye test that the company says determines a patient’s likelihood of contracting age-related macular degeneration (AMD).”
Visible Genomics Launches DNA Age-Related Macular Degeneration Testing - INVISION
“CHICAGO, IL — Visible Genomics, a Chicago-area genetics testing company has announced the launch of a new non-invasive genetic eye test that determines a patient’s likelihood of contracting Age-Related Macular Degeneration (AMD), a disease that causes blindness. AMD affects the macular, the central part of the retina, and is one of the leading causes of irreversible vision loss in the United States, affecting over 11 million Americans.”
Visible Genomics Launches DNA Age-Related Macular Degeneration Testing - OptaZoom
“CHICAGO—Visible Genomics, a Chicago-area genetics testing company has announced the launch of a new non-invasive genetic eye test that determines a patient’s likelihood of contracting age-related macular degeneration (AMD), a disease that causes blindness. While it’s estimated that up to 70 percent of AMD cases are due to genetics…”
Visible Genomics Announces Four New Appointments to Board of Clinical Advisors - Biospace
"We are pleased to welcome Barry, Steve, Alan, and Treacy as our new independent team of clinical advisors to the Visible Genomics board, and we especially value their range of medical optometry research and experience,” said Frank Adamo, Founder and CEO of Visible Genomics. "They join Visible Genomics at an exciting time as we launch a non-invasive genetic eye test for AMD. Our new board will be instrumental in building deeper relationships with doctors as well as patients, fulfilling our purpose of helping people keep their vision healthy.”
Visible Genomics hires clinical advisers to prep for macular degeneration test - Chicago Business Journal
“The company is preparing to launch a non-invasive genetic eye test that can determine a patient's likelihood of contracting age-related macular degeneration.”